Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON 2 for relapsed neuroblastoma
2024-516115-24-00Phase 2Authorised
- Sponsor
- University of Birmingham
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of Dinutuximab beta, bevacizumab, temozolomide, topotecan and irinotecan in neuroblastoma (4 arms), sponsored by University of Birmingham. Primary endpoints: Progression-free survival and Safe and tolerable combination regimen. Planned start Jul 2026; status: authorised.
02
Drugs
Dinutuximab betabevacizumabtemozolomidetopotecanirinotecan
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2024-516115-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516115-24-00.